| P50 | author | M. Maral Mouradian | Q56854792 |
| P2093 | author name string | Hideki Mochizuki | |
| | Toru Yasuda | |
| P2860 | cites work | Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration | Q45888308 |
| | In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector | Q45889326 |
| | Morphological and neurochemical features of cultured primary skin fibroblasts of Fischer 344 rats following striatal implantation | Q46012400 |
| | Targeting of marrow-derived astrocytes to the ischemic brain | Q48190295 |
| | Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys | Q48197305 |
| | Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys | Q48325968 |
| | Neuronal specificity of alpha-synuclein toxicity and effect of Parkin co-expression in primates | Q48371876 |
| | Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? | Q48390998 |
| | Cellular and functional recovery of Parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. | Q48517875 |
| | DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice. | Q54105201 |
| | Gene therapy for Parkinson's disease | Q64382253 |
| | Second chance | Q80584692 |
| | DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice | Q45865989 |
| | Neural-targeted gene therapy for rodent and primate hemiparkinsonism | Q45866224 |
| | Astrocytes retrovirally transduced with BDNF elicit behavioral improvement in a rat model of Parkinson's disease | Q45876215 |
| | Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts | Q45877347 |
| | L-Dopa and dopamine-producing gene cassettes for gene therapy approaches to Parkinson's disease | Q45881504 |
| | Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease | Q45881923 |
| | Gene therapy for Parkinson's disease: current knowledge and future perspective | Q45882774 |
| | Role of aromatic L-amino acid decarboxylase for dopamine replacement by genetically modified fibroblasts in a rat model of Parkinson's disease. | Q45884094 |
| | Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase | Q22254584 |
| | Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 |
| | Neurturin, a relative of glial-cell-line-derived neurotrophic factor | Q24324692 |
| | Dopamine covalently modifies and functionally inactivates parkin | Q24338423 |
| | Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice | Q24534272 |
| | Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease | Q28187904 |
| | Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease | Q28202050 |
| | S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function | Q28258212 |
| | Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons | Q28274311 |
| | AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease | Q28304068 |
| | Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease | Q28588314 |
| | Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. | Q28593258 |
| | Heat shock protein 70 inhibits alpha-synuclein fibril formation via preferential binding to prefibrillar species | Q28910363 |
| | Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin | Q29547423 |
| | Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin | Q29615684 |
| | Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin | Q29617063 |
| | Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity | Q30448692 |
| | Induction of neostriatal neurogenesis slows disease progression in a transgenic murine model of Huntington disease | Q30480065 |
| | Differentiation of transplanted bone marrow cells in the adult mouse brain | Q30688731 |
| | Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease | Q33228383 |
| | Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats | Q33745707 |
| | From marrow to brain: expression of neuronal phenotypes in adult mice. | Q33926766 |
| | Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow | Q33926770 |
| | An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease | Q33943954 |
| | Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease | Q34086449 |
| | Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. | Q34088742 |
| | Subthalamic GAD gene therapy in a Parkinson's disease rat model | Q34154186 |
| | Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease | Q34320662 |
| | Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers | Q34450342 |
| | Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial | Q34640765 |
| | Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies | Q34763209 |
| | Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain | Q35171498 |
| | Clinical trials in neurological disorders using AAV vectors: promises and challenges. | Q35945112 |
| | Engraftment and migration of human bone marrow stromal cells implanted in the brains of albino rats--similarities to astrocyte grafts | Q36012180 |
| | Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice | Q36109567 |
| | New recombinant serotypes of AAV vectors. | Q36172991 |
| | What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports | Q36202008 |
| | Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. | Q36227173 |
| | Genetics of Parkinson disease: paradigm shifts and future prospects. | Q36423921 |
| | Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. | Q36561684 |
| | Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice | Q37131550 |
| | Site-specific integration by adeno-associated virus | Q37246710 |
| | Genetically altered and defined cell lines for transplantation in animal models of Parkinson's disease | Q37610792 |
| | Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease | Q37713838 |
| | Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease | Q40242764 |
| | Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model | Q40320292 |
| | Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease | Q40326219 |
| | Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease | Q40348917 |
| | Lentivirus-mediated expression of glutathione peroxidase: neuroprotection in murine models of Parkinson's disease | Q40397185 |
| | Clinico-pathological rescue of a model mouse of Huntington's disease by siRNA. | Q40397746 |
| | Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. | Q40416751 |
| | Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. | Q40462605 |
| | Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease | Q40511251 |
| | Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. | Q40524258 |
| | Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation | Q40544827 |
| | Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons | Q40546525 |
| | AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington disease | Q40560840 |
| | Trophic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body-grafted parkinsonian rats. | Q40679335 |
| | Protection of nigral neurons by GDNF-engineered marrow cell transplantation | Q40791211 |
| | Neurturin protects striatal projection neurons but not interneurons in a rat model of Huntington's disease | Q40873179 |
| | Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. | Q40906953 |
| | Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model | Q40941898 |
| | Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle | Q40958690 |
| | A commentary on glial cell line-derived neurotrophic factor (GDNF). From a glial secreted molecule to gene therapy | Q40980458 |
| | Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. | Q40983409 |
| | Behavioral recovery in 6-hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors | Q40988268 |
| | Efficacy of grafted immortalized dopamine neurons in an animal model of parkinsonism: a review | Q41000320 |
| | Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease | Q41068462 |
| | Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain | Q41090635 |
| | The coming of age of the GDNF family and its receptors: gene delivery in a rat Parkinson model may have clinical implications | Q41102311 |
| | Dopaminergic neurons protected from degeneration by GDNF gene therapy | Q41128316 |
| | Expression of tyrosine hydroxylase in an immortalized human fetal astrocyte cell line; in vitro characterization and engraftment into the rodent striatum | Q41222328 |
| | Genetically modified PC12 brain grafts: survivability and inducible nerve growth factor expression | Q41252695 |
| | Gene therapy for Parkinson's disease: an approach to the prevention or palliation of levodopa-associated motor complications | Q41450662 |
| | Tetrahydrobiopterin-dependent functional recovery in 6-hydroxydopamine-treated rats by intracerebral grafting of fibroblasts transfected with tyrosine hydroxylase cDNA | Q41649774 |
| | Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain | Q42280576 |
| | Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease | Q42446285 |
| | Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase | Q43185222 |
| | Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. | Q43707952 |
| | Survival of genetically engineered, adult-derived rat astrocytes grafted into the 6-hydroxydopamine lesioned adult rat striatum | Q43762264 |
| | Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease | Q44769508 |
| | Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus | Q44898080 |
| | Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease | Q45304363 |
| | Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. | Q45756120 |
| | Toward autologous ex vivo gene therapy for the central nervous system with human adult astrocytes | Q45856349 |
| | Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice | Q45858191 |
| | Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. | Q45859568 |
| | Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism | Q45859700 |
| P433 | issue | 2 | |
| P921 | main subject | gene therapy | Q213901 |
| P304 | page(s) | 260-269 | |
| P577 | publication date | 2008-04-01 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Advances in gene therapy for movement disorders | |
| P478 | volume | 5 | |